Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using Ga-PSMA PET/CT
Standard
Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using Ga-PSMA PET/CT. / Bieth, Marie; Krönke, Markus; Tauber, Robert; Dahlbender, Marielena; Retz, Margitta; Nekolla, Stephan G; Menze, Bjoern; Maurer, Tobias; Eiber, Matthias; Schwaiger, Markus.
In: J NUCL MED, Vol. 58, No. 10, 10.2017, p. 1632-1637.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using Ga-PSMA PET/CT
AU - Bieth, Marie
AU - Krönke, Markus
AU - Tauber, Robert
AU - Dahlbender, Marielena
AU - Retz, Margitta
AU - Nekolla, Stephan G
AU - Menze, Bjoern
AU - Maurer, Tobias
AU - Eiber, Matthias
AU - Schwaiger, Markus
N1 - © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2017/10
Y1 - 2017/10
N2 - PET combined with CT and prostate-specific membrane antigen (PSMA) ligands has gained significant interest for staging prostate cancer (PC). In this study, we propose 2 multimodal quantitative indices as imaging biomarkers for the assessment of osseous tumor burden using 68Ga-PSMA PET/CT and present preliminary clinical data. Methods: We defined 2 bone PET indices (BPIs) that incorporate anatomic information from CT and functional information from 68Ga-PSMA PET: BPIVOL is the percentage of bone volume affected by tumor and BPISUV additionally considers the level of PSMA expression. We describe a semiautomatic computation method based on segmentation of bones in CT and of lesions in PET. Data from 45 patients with castration-resistant PC and bone metastases during 223Ra-dichloride were retrospectively analyzed. We evaluated the computational stability and reproducibility of the proposed indices and explored their relation to the prostate-specific antigen blood value, the bone scan index (BSI), and disease classification using PERCIST. Results: On the technical side, BPIVOL and BPISUV showed an interobserver maximum difference of 3.5%, and their computation took only a few minutes. On the clinical side, BPIVOL and BPISUV showed significant correlations with BSI (r = 0.76 and 0.74, respectively, P < 0.001) and prostate-specific antigen values (r = 0.57 and 0.54, respectively, P < 0.01). When the proposed indices were compared against expert rating using PERCIST, BPIVOL and BPISUV showed better agreement than BSI, indicating their potential for objective response evaluation. Conclusion: We propose the evaluation of BPIVOL and BPISUV as imaging biomarkers for 68Ga-PSMA PET/CT in a prospective study exploring their potential for outcome prediction in patients with bone metastases from PC.
AB - PET combined with CT and prostate-specific membrane antigen (PSMA) ligands has gained significant interest for staging prostate cancer (PC). In this study, we propose 2 multimodal quantitative indices as imaging biomarkers for the assessment of osseous tumor burden using 68Ga-PSMA PET/CT and present preliminary clinical data. Methods: We defined 2 bone PET indices (BPIs) that incorporate anatomic information from CT and functional information from 68Ga-PSMA PET: BPIVOL is the percentage of bone volume affected by tumor and BPISUV additionally considers the level of PSMA expression. We describe a semiautomatic computation method based on segmentation of bones in CT and of lesions in PET. Data from 45 patients with castration-resistant PC and bone metastases during 223Ra-dichloride were retrospectively analyzed. We evaluated the computational stability and reproducibility of the proposed indices and explored their relation to the prostate-specific antigen blood value, the bone scan index (BSI), and disease classification using PERCIST. Results: On the technical side, BPIVOL and BPISUV showed an interobserver maximum difference of 3.5%, and their computation took only a few minutes. On the clinical side, BPIVOL and BPISUV showed significant correlations with BSI (r = 0.76 and 0.74, respectively, P < 0.001) and prostate-specific antigen values (r = 0.57 and 0.54, respectively, P < 0.01). When the proposed indices were compared against expert rating using PERCIST, BPIVOL and BPISUV showed better agreement than BSI, indicating their potential for objective response evaluation. Conclusion: We propose the evaluation of BPIVOL and BPISUV as imaging biomarkers for 68Ga-PSMA PET/CT in a prospective study exploring their potential for outcome prediction in patients with bone metastases from PC.
KW - Antigens, Surface
KW - Bone Neoplasms
KW - Gallium Radioisotopes
KW - Glutamate Carboxypeptidase II
KW - Humans
KW - Male
KW - Positron Emission Tomography Computed Tomography
KW - Prostatic Neoplasms, Castration-Resistant
KW - Retrospective Studies
KW - Tumor Burden
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.2967/jnumed.116.189050
DO - 10.2967/jnumed.116.189050
M3 - SCORING: Journal article
C2 - 28546330
VL - 58
SP - 1632
EP - 1637
JO - J NUCL MED
JF - J NUCL MED
SN - 0161-5505
IS - 10
ER -